Clinical trials: ACTH, active
Pituitary Adenoma, Cushing Disease
Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
This pilot and feasibility study aims to combine recent advances in ultrasound imaging, specifically an endonasal transducer array and contrast enhanced ultrasound, to offer an intraoperative image-guided solution for…
- Trial name
- NCT07335315
- Testing
- Contrast enhanced pituitary magnetic resonance imaging (MRI), Contrast enhanced ultrasound, Non-Contrast Ultrasound
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Mayo Clinic
Cushing Disease, ACTH-producing Pituitary Tumour
Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.
Cushing's disease results from adrenocorticotropic hormone (ACTH) secretion by corticotroph pituitary neuroendocrine tumors (PitNETs).
- Trial name
- PiTFET (NCT07463625)
- Testing
- Data-only evaluation of [18F]FET PET, pituitary MRI, and biomarkers
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Primary Aldosteronism
Sequential Combined Versus Single-Strategy Adrenal Venous Sampling for Primary Aldosteronism(SCOPE)
This study is a prospective, multicenter, randomized clinical trial aimed to compare the impact of three AVS diagnostic strategies on the clinical outcomes of patients with primary aldosteronism.
- Trial name
- NCT07298954
- Testing
- sequential combined AVS
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Shumin Yang
Cushing s Syndrome
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome
In previous clinical practice, 68Ga-Pentixafor PET/CT has demonstrated promising diagnostic utility in various neuroendocrine tumors by targeting CXCR4, a chemokine receptor overexpressed in several ACTH-secreting neoplasms.
- Trial name
- NCT07350707
- Testing
- 68Ga-Pentixafor
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peking Union Medical College Hospital
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Gynecologic Laparoscopic Surgery
COMPARISON OF OXIDANT-ANTIOXIDANT LEVELS WITH STRESS HORMONES IN SPINAL ANESTHESIA AND GENERAL ANESTHESIA IN LAPAROSCOPIC TUBE LIGATION
The aim of this observational study is to investigate the effect of anesthesia method applied in laparoscopic tubal ligation on stress factors in women aged 15-45.
- Trial name
- LAP TUBE LİG (NCT06710522)
- Where
- Turkey (Türkiye)
- Volunteers
- 136 people
- Sponsor
- KADİR TEOMAN
Nephrotic Syndrome in Children
Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized，Open-label Clinical Trial.
Primary nephrotic syndrome accounts for approximately 90% of the total number of nephrotic syndrome in childhood and it is the most common glomerular disease in children.
- Trial name
- NCT06079788
- Testing
- Adrenocorticotrophic Hormone, Steroid
- Where
- 8 sites in China
- Volunteers
- 140 people
- Sponsor
- Mao Jianhua
Cushing Disease
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
Supported by the pre-clinical data (summarized in Research Strategy), the investigators propose that Fimepinostat is an ideal candidate drug in the treatment and intervention of patients with Cushing Disease.
- Trial name
- NCT05971758
- Testing
- Fimepinostat
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Multiple Sclerosis
Acupressure in MS Patients
This study aims to evaluate the effects of acupressure therapy on patients with Multiple Sclerosis (MS). MS is a chronic autoimmune disease affecting the central nervous system, characterized by inflammation, demyelination, and…
- Trial name
- APEX-MS (NCT06755463)
- Testing
- Self-acupressure education
- Volunteers
- 82 people
- Sponsor
- Abant Izzet Baysal University
Cushing's Disease
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol.
- Trial name
- BalanCeD (NCT06471829)
- Testing
- Lu AG13909
- Where
- 27 sites in United States, France and 7 more
- Volunteers
- 16 people
- Sponsor
- H. Lundbeck A/S
Cushing Disease
Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
Background: The pituitary gland produces hormones. A tumor in this gland can cause it to produce too much of the hormone cortisol. Too much cortisol in the body causes Cushing disease. This disease causes many problems.
- Trial name
- NCT03831958
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Nightmare
Nightmare Deconstruction and Reprocessing vs. NightWare Wristband
The overall goal of this Phase IIa randomized controlled pilot trial is to assess the potential efficacy of two emerging treatments for post-trauma nightmares and to test the feasibility of study design and methods.
- Trial name
- NDR/NW (NCT06399874)
- Testing
- Nightmare Deconstruction and Reprocessing, NightWare
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Uniformed Services University of the Health Sciences
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS
single-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of overnight metyrapone in patients with MACS.
- Trial name
- NCT07138274
- Testing
- Metyrapone 250 mg Oral Tablets
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Mayo Clinic
Cushing Syndrome, Adrenal Insufficiency
Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders
This is a multicentric, prospective, intervention study on circadian genes expression in peripheral blood mononuclear cells as biomarkers of circadian rhythm derangement in patients affected by alterations of endogenous…
- Conditions
- Cushing Syndrome, Adrenal Insufficiency, Cushing Disease, Addison Disease
- Trial name
- CHROnOS (NCT04374721)
- Testing
- circadian gene expression evaluation
- Where
- Italy
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Cushing Disease
Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease
In ACTH-dependent hypercortisolism it is important to distinguish between Cushing's disease (CD), with ACTH production by a pituitary neuroendocrine tumour (PitNET) and Cushing's syndrome (CS), with ectopic ACTH production.
- Trial name
- FIND (NCT07108244)
- Testing
- [18F]FET PET-MRI
- Where
- 2 sites in Netherlands, Switzerland
- Volunteers
- 43 people
- Sponsor
- University Hospital, Basel, Switzerland
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with…
- Conditions
- Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
- Trial name
- IMPACT-MACS (NCT07361874)
- Testing
- Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Texas Southwestern Medical Center
Cushing's Disease, Pituitary Adenoma
DDAVP for Pituitary Adenoma
This study is designed as a single institution trial. The study utilizes safe and clinically-validated tools for preoperative workup of patients with small pituitary tumors.
- Trial name
- NCT04569591
- Testing
- Desmopressin acetate
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Cushing Syndrome
Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CT
The incidence of Cushing syndrome (CS) is 1.2-3.2 cases per million per year, of which adrenocorticotropic Hormone (ACTH)-dependent disease comprises approximately 70-80% of cases.
- Trial name
- Ga-68 mDesmo (NCT06962202)
- Where
- India
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Adrenal Adenoma, Cushing Syndrome
A Prospective Cohort Study for Patients With Adrenal Diseases
The purpose of this study is to investigate the pathologic features, complications, and prognostic factors of functioning adrenal adenoma and suggest follow-up algorithms for adrenal incidentaloma.
- Conditions
- Adrenal Adenoma, Cushing Syndrome, Pheochromocytoma, Adrenal Incidentaloma
- Trial name
- NCT03474237
- Testing
- Hormone study and Imaging study
- Where
- South Korea
- Volunteers
- 1,500 people
- Sponsor
- Seoul National University Hospital
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International